Moleculin Biotech Other Current Assets Over Time
| MBRX Stock | USD 2.77 0.08 2.97% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Moleculin Biotech Performance and Moleculin Biotech Correlation. Moleculin |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moleculin Biotech. If investors know Moleculin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moleculin Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (12.04) | Return On Assets (0.57) | Return On Equity (1.41) |
The market value of Moleculin Biotech is measured differently than its book value, which is the value of Moleculin that is recorded on the company's balance sheet. Investors also form their own opinion of Moleculin Biotech's value that differs from its market value or its book value, called intrinsic value, which is Moleculin Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moleculin Biotech's market value can be influenced by many factors that don't directly affect Moleculin Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moleculin Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Moleculin Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moleculin Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Other Current Assets Analysis
Compare Moleculin Biotech and related stocks such as Catalyst Biosciences, Pulmatrix, and Cyclacel Pharmaceuticals Other Current Assets Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PULM | 4 K | 4 K | 4 K | 3 K | 3 K | 1.1 M | 371 K | 695 K | 27 K | 221 K | 723 K | 871 K | 1.1 M | 1.1 M | 566.2 K |
| CYCC | 519 K | 1.2 M | 861 K | 639 K | 278 K | 132 K | 41 K | 81 K | 170 K | 103 K | 750 K | 4.4 M | 6.1 M | 4.1 M | 4.3 M |
| AKTX | 142 K | 142 K | 142 K | 142 K | 142 K | 730 K | 1.5 M | 706.4 K | 706.4 K | 1 M | 521.9 K | 2.3 M | 564.8 K | 496 K | 954.4 K |
| BPTH | 1.0 | 48.4 K | 42.6 K | 64.1 K | 100.5 K | 179 K | 902 K | 353 K | 593 K | 788 K | 2.2 M | 2.4 M | 5.2 M | 2 M | 2.1 M |
| ANTX | 102 K | 102 K | 102 K | 102 K | 102 K | 102 K | 102 K | 102 K | 102 K | 102 K | 164 K | 1.6 M | 2.6 M | 3.2 M | 1.7 M |
| IKT | 399.1 K | 399.1 K | 399.1 K | 399.1 K | 399.1 K | 399.1 K | 399.1 K | 399.1 K | 399.1 K | 16.9 K | 829.2 K | 1.6 M | 163.5 K | 959 K | 729.2 K |
| PMVP | 332 K | 332 K | 332 K | 332 K | 332 K | 332 K | 332 K | 332 K | 332 K | 607 K | 6.7 M | 4.1 M | 6 M | 4.4 M | 4 M |
| ANEB | 3.5 | 3.5 | 3.5 | 3.5 | 3.5 | 3.5 | 3.5 | 3.5 | 3.5 | 3.5 | 1.7 M | 1 M | 422.7 K | 413.8 K | 565.7 K |
| CAPR | 526.3 K | 271.3 K | 124.9 K | 222.8 K | 235.5 K | 210.6 K | 342.9 K | 501.2 K | 724.2 K | 571.4 K | 1 M | 1.2 M | 919.9 K | 995.8 K | 572 K |
| NXTC | 133 K | 133 K | 133 K | 133 K | 133 K | 133 K | 133 K | 133 K | 152 K | 3.7 M | 4.5 M | 8.2 M | 4.1 M | 4.4 M | 4 M |
| VRAX | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 6 K | 281.5 K | 512.8 K | 538.4 K |
| ALLR | 163 K | 163 K | 163 K | 163 K | 163 K | 163 K | 163 K | 163 K | 163 K | 163 K | 174 K | 36 K | 2.1 M | 859 K | 726 K |
| ATXI | 388 K | 388 K | 388 K | 388 K | 388 K | 388 K | 388 K | 388 K | 152 K | 170 K | 113 K | 107 K | 137 K | 67 K | 129.6 K |
Moleculin Biotech and related stocks such as Catalyst Biosciences, Pulmatrix, and Cyclacel Pharmaceuticals Other Current Assets description
Assets expected to be converted into cash, sold, or consumed either in one year or in the operating cycle, which are not included under standard current asset categories.My Equities
My Current Equities and Potential Positions
| Moleculin Biotech | MBRX |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Texas; U.S.A |
| Exchange | NASDAQ Exchange |
USD 2.77
Additional Tools for Moleculin Stock Analysis
When running Moleculin Biotech's price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.